New STTR grant supporting BKM1644 study

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the mechanism of action and in vivo efficacy of a novel small-molecule compound (BKM1644) in treating prostate cancer.

Project Details:

Enzalutamide resistance is a major obstacle in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). Recently we developed a small-molecule lead compound BKM1644 and demonstrated its potent activity against bone metastatic prostate cancer cells. In this Phase I STTR application, we hypothesize that BKM1644 is a novel targeted therapy to overcome enzalutamide resistance and effectively target bone metastasis. Two Aims are proposed: Aim 1 will evaluate the in vivo pharmacokinetics, distribution and efficacy of BKM1644 in targeting enzalutamide-resistant, bone metastatic prostate cancer in animal models. Aim 2 will determine the mechanism of action of BKM1644 in mCRPC cells. The project has immediate therapeutic potential in treating a lethal disease.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s